Results 31 to 40 of about 130,251 (209)

Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population [PDF]

, 2016
The identification of signaling pathways that affect the cancer stem-like phenotype may provide insights into therapeutic targets for combating embryonal rhabdomyosarcoma.
Ciccarelli, Carmela, DI PAOLO, Virginia, Giampaolo, Adele, Gravina, GIOVANNI LUCA, Hassan, Hamisa Jane, Macioce, Giampiero, Marampon, Francesco, Milazzo, Luisa, Tombolini, Vincenzo, Vulcano, Francesca, Zani, Bianca Maria   +10 more
core   +9 more sources

Current Development Status of MEK Inhibitors [PDF]

Molecules, 2017
The current development status of mitogen-activated protein kinase kinase (MEK) inhibitors, including the preclinical data and clinical study progress, has been summarized in this review. Different MEK inhibitors, possessing specific physicochemical properties and bioactivity characteristics, may provide different options for patients seeking treatment
Ying Cheng, Hongqi Tian
openaire   +3 more sources

Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers

Cell Reports, 2019
Summary: The mitogen-activated protein kinase (MAPK) pathway is a critical effector of oncogenic RAS signaling, and MAPK pathway inhibition may be an effective combination treatment strategy. We performed genome-scale loss-of-function CRISPR-Cas9 screens
Rita Sulahian, Jason J. Kwon, Katherine H. Walsh, Emma Pailler, Timothy L. Bosse, Maneesha Thaker, Diego Almanza, Joshua M. Dempster, Joshua Pan, Federica Piccioni, Nancy Dumont, Alfredo Gonzalez, Jonathan Rennhack, Behnam Nabet, John A. Bachman, Amy Goodale, Yenarae Lee, Mukta Bagul, Rosy Liao, Adrija Navarro, Tina L. Yuan, Raymond W.S. Ng, Srivatsan Raghavan, Nathanael S. Gray, Aviad Tsherniak, Francisca Vazquez, David E. Root, Ari J. Firestone, Jeff Settleman, William C. Hahn, Andrew J. Aguirre   +30 more
doaj   +1 more source

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. [PDF]

PLoS ONE, 2011
The sustained clinical activity of the BRAF inhibitor vemurafenib (PLX4032/RG7204) in patients with BRAF(V600) mutant melanoma is limited primarily by the development of acquired resistance leading to tumor progression.
Mohammad Atefi, Erika von Euw, Narsis Attar, Charles Ng, Connie Chu, Deliang Guo, Ramin Nazarian, Bartosz Chmielowski, John A Glaspy, Begonya Comin-Anduix, Paul S Mischel, Roger S Lo, Antoni Ribas   +12 more
doaj   +1 more source

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers

Genome Medicine, 2018
Background Mutations in KRAS are frequent in human cancer, yet effective targeted therapeutics for these cancers are still lacking. Attempts to drug the MEK kinases downstream of KRAS have had limited success in clinical trials.
Tonći Šuštić, Sake van Wageningen, Evert Bosdriesz, Robert J. D. Reid, John Dittmar, Cor Lieftink, Roderick L. Beijersbergen, Lodewyk F. A. Wessels, Rodney Rothstein, René Bernards   +9 more
doaj   +1 more source

Integration of a Phosphatase Cascade with the MAP Kinase Pathway provides for a Novel Signal Processing Function [PDF]

, 2009
We mathematically modeled the receptor-activated MAP kinase signaling by incorporating the regulation through cellular phosphatases. Activation induced the alignment of a phosphatase cascade in parallel with the MAP kinase pathway.
Alon, Altan-Bonnet, Bettini, Bhalla, Birtwistle, Blüthgen, Bollen, Brondello, Camps, Castelli, Chang, Cobb, Cyert, Das, Dickinson, Dickinson, Ebisuya, Echevarria, Eungdamrong, Ferrell, Friedman, Hatakeyama, Heinrich, Huang, Karlsson, Keyse, Kholodenko, Kolch, Kolch, Kumar, Kumar, Kurosaki, Kurosaki, Kurosaki, Kurosaki, Kurosaki, Levchenko, Locasale, Manders, Muda, Orton, Qiao, Raman, Reth, Rolli, Santos, Schmidt, Singh, Tan, Tian, Ueki, Widmann, Zandomeni, Zhao, Zi   +54 more
core   +3 more sources

A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC. [PDF]

PLoS ONE, 2018
Mutant KRAS represents one of the most frequently observed oncogenes in NSCLC, yet no therapies are approved for tumors that express activated KRAS variants. While there is strong rationale for the use of MEK inhibitors to treat tumors with activated RAS/
Nicholas Dompe, Christiaan Klijn, Sara A Watson, Katherine Leng, Jenna Port, Trinna Cuellar, Colin Watanabe, Benjamin Haley, Richard Neve, Marie Evangelista, David Stokoe   +10 more
doaj   +1 more source

Inhibition of MEK-ERK pathway enhances oncolytic vaccinia virus replication in doxorubicin-resistant ovarian cancer

Molecular Therapy: Oncolytics, 2022
Oncolytic vaccinia virus (OVV) has been reported to induce cell death in various types of cancer; however, the oncolytic activity of OVV in drug-resistant ovarian cancer remains limited.
Seoyul Lee, Wookyeom Yang, Dae Kyoung Kim, Hojun Kim, Minjoo Shin, Kyung Un Choi, Dong Soo Suh, Yun Hak Kim, Tae-Ho Hwang, Jae Ho Kim   +9 more
doaj   +1 more source

Targeting Oncogenic BRAF: Past, Present, and Future. [PDF]

, 2019
Identifying recurrent somatic genetic alterations of, and dependency on, the kinase BRAF has enabled a "precision medicine" paradigm to diagnose and treat BRAF-driven tumors.
Bivona, Trever G, Wu, Wei, Zaman, Aubhishek   +2 more
core   +1 more source

Off-Target Effects of MEK Inhibitors [PDF]

Biochemistry, 2013
The mitogen-activated protein kinases (MAPKs) ERK1/2 regulate numerous cellular processes, including gene transcription, proliferation, and differentiation. The only known substrates of the MAP2Ks MEK1/2 are ERK1/2; thus, MEK inhibitors PD98059, U0126, and PD0325901 have been important tools in determining the functions of ERK1/2.
Eric M, Wauson, Marcy L, Guerra, Barbara, Barylko, Joseph P, Albanesi, Melanie H, Cobb   +4 more
openaire   +2 more sources